File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Improved final height in girls with Turner's syndrome treated with growth hormone and oxandrolone

TitleImproved final height in girls with Turner's syndrome treated with growth hormone and oxandrolone
Authors
Issue Date1996
PublisherThe Endocrine Society. The Journal's web site is located at http://jcem.endojournals.org
Citation
Journal Of Clinical Endocrinology And Metabolism, 1996, v. 81 n. 2, p. 635-640 How to Cite?
AbstractThe spontaneous growth process in Turner's syndrome is characterized by a progressive decline in height velocity during childhood and no pubertal growth spurt. Therefore, therapy aimed at improving height during childhood as well as increasing final height is desirable for most girls with Turner's syndrome. Forty-five girls with Turner's syndrome, 9-16 yr of age (mean age, 12.2 yr), were allocated to three study groups. Group 1 (n = 13) was initially treated with oxandrolone alone; after 1 yr of treatment, GH without (group 1a; n = 6) or with (group 1b; n = 7) ethinyl estradiol was added. Group 2 (n = 17) was treated with GH plus oxandrolone. Group 3 (n = 15) was treated with GH, oxandrolone, and ethinyl estradiol. The dosages were: GH, 0.1 IU/kg · day; oxandrolone, 0.05 mg/kg · day; and ethinyl estradiol, 100 ng/kg · day. A height of 150 cm or more was achieved in 61%, 75%, and 60% of the girls in groups 1, 2, and 3, respectively. The most impressive increase in height was seen in group 2. In this group the mean final height was 154.2 cm (SD = 6.6), which is equivalent to a mean net gain of 8.5 cm (SD = 4.6) over the projected final height. In group 3, in which ethinyl estradiol was included from the start of therapy, the initially good height velocity decelerated after 1-2 yr of treatment. Their mean final height was 151.1 (SD = 4.6) cm, equivalent to a mean net gain of 3.0 cm (SD = 3.8). A similar growth-decelerating effect of ethinyl estradiol was seen in group 1b. We conclude that in girls with Turner's syndrome who are older than 9 yr of age, treatment with GH in combination with oxandrolone results in significant growth acceleration, imitating that in normal puberty, leading to a more favorable height during childhood. This mode of treatment also results in a significantly increased final height, permitting a great number of the girls to attain a final height of more than 150 cm. However, early addition of estrogen decelerates the height velocity and reduces the gain in height.
Persistent Identifierhttp://hdl.handle.net/10722/49392
ISSN
2015 Impact Factor: 5.531
2015 SCImago Journal Rankings: 2.940
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorNilsson, KOen_HK
dc.contributor.authorAlbertssonWikland, Ken_HK
dc.contributor.authorAlm, Jen_HK
dc.contributor.authorAronson, Sen_HK
dc.contributor.authorGustafsson, Jen_HK
dc.contributor.authorHagenäs, Len_HK
dc.contributor.authorHäger, Aen_HK
dc.contributor.authorIvarsson, SAen_HK
dc.contributor.authorKarlberg, Jen_HK
dc.contributor.authorKriström, Ben_HK
dc.contributor.authorMarcus, Cen_HK
dc.contributor.authorMoell, Cen_HK
dc.contributor.authorRitzén, Men_HK
dc.contributor.authorTuvemo, Ten_HK
dc.contributor.authorWattsgård, Cen_HK
dc.contributor.authorWestgren, Uen_HK
dc.contributor.authorWestphal, Oen_HK
dc.contributor.authorÅman, Jen_HK
dc.date.accessioned2008-06-12T06:41:17Z-
dc.date.available2008-06-12T06:41:17Z-
dc.date.issued1996en_HK
dc.identifier.citationJournal Of Clinical Endocrinology And Metabolism, 1996, v. 81 n. 2, p. 635-640en_HK
dc.identifier.issn0021-972Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/49392-
dc.description.abstractThe spontaneous growth process in Turner's syndrome is characterized by a progressive decline in height velocity during childhood and no pubertal growth spurt. Therefore, therapy aimed at improving height during childhood as well as increasing final height is desirable for most girls with Turner's syndrome. Forty-five girls with Turner's syndrome, 9-16 yr of age (mean age, 12.2 yr), were allocated to three study groups. Group 1 (n = 13) was initially treated with oxandrolone alone; after 1 yr of treatment, GH without (group 1a; n = 6) or with (group 1b; n = 7) ethinyl estradiol was added. Group 2 (n = 17) was treated with GH plus oxandrolone. Group 3 (n = 15) was treated with GH, oxandrolone, and ethinyl estradiol. The dosages were: GH, 0.1 IU/kg · day; oxandrolone, 0.05 mg/kg · day; and ethinyl estradiol, 100 ng/kg · day. A height of 150 cm or more was achieved in 61%, 75%, and 60% of the girls in groups 1, 2, and 3, respectively. The most impressive increase in height was seen in group 2. In this group the mean final height was 154.2 cm (SD = 6.6), which is equivalent to a mean net gain of 8.5 cm (SD = 4.6) over the projected final height. In group 3, in which ethinyl estradiol was included from the start of therapy, the initially good height velocity decelerated after 1-2 yr of treatment. Their mean final height was 151.1 (SD = 4.6) cm, equivalent to a mean net gain of 3.0 cm (SD = 3.8). A similar growth-decelerating effect of ethinyl estradiol was seen in group 1b. We conclude that in girls with Turner's syndrome who are older than 9 yr of age, treatment with GH in combination with oxandrolone results in significant growth acceleration, imitating that in normal puberty, leading to a more favorable height during childhood. This mode of treatment also results in a significantly increased final height, permitting a great number of the girls to attain a final height of more than 150 cm. However, early addition of estrogen decelerates the height velocity and reduces the gain in height.en_HK
dc.format.extent418 bytes-
dc.format.mimetypetext/html-
dc.languageengen_HK
dc.publisherThe Endocrine Society. The Journal's web site is located at http://jcem.endojournals.orgen_HK
dc.relation.ispartofJournal of Clinical Endocrinology and Metabolismen_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.rightsJournal of Clinical Endocrinology and Metabolism. Copyright © The Endocrine Society.en_HK
dc.subject.meshAnabolic Agents - therapeutic useen_HK
dc.subject.meshBody Heighten_HK
dc.subject.meshGrowth Hormone - therapeutic useen_HK
dc.subject.meshOxandrolone - therapeutic useen_HK
dc.subject.meshTurner Syndrome - drug therapy - physiopathologyen_HK
dc.titleImproved final height in girls with Turner's syndrome treated with growth hormone and oxandroloneen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0021-972X&volume=81&issue=2&spage=635&epage=640&date=1996&atitle=Improved+final+height+in+girls+with+Turner%27s+syndrome+treated+with+growth+hormone+and+oxandroloneen_HK
dc.identifier.emailKarlberg, J: jpekarl@hkucc.hku.hken_HK
dc.identifier.authorityKarlberg, J=rp00400en_HK
dc.description.naturepublished_or_final_versionen_HK
dc.identifier.doi10.1210/jc.81.2.635en_HK
dc.identifier.pmid8636281-
dc.identifier.scopuseid_2-s2.0-9044247068en_HK
dc.identifier.hkuros10116-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-9044247068&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume81en_HK
dc.identifier.issue2en_HK
dc.identifier.spage635en_HK
dc.identifier.epage640en_HK
dc.identifier.isiWOS:A1996TU98100038-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridNilsson, KO=7202864742en_HK
dc.identifier.scopusauthoridAlbertssonWikland, K=19639814800en_HK
dc.identifier.scopusauthoridAlm, J=24340617700en_HK
dc.identifier.scopusauthoridAronson, S=7202182723en_HK
dc.identifier.scopusauthoridGustafsson, J=36014564800en_HK
dc.identifier.scopusauthoridHagenäs, L=7003589762en_HK
dc.identifier.scopusauthoridHäger, A=7005597215en_HK
dc.identifier.scopusauthoridIvarsson, SA=7004869731en_HK
dc.identifier.scopusauthoridKarlberg, J=7005218406en_HK
dc.identifier.scopusauthoridKriström, B=6603784721en_HK
dc.identifier.scopusauthoridMarcus, C=7103039681en_HK
dc.identifier.scopusauthoridMoell, C=6701489079en_HK
dc.identifier.scopusauthoridRitzén, M=7004087512en_HK
dc.identifier.scopusauthoridTuvemo, T=7004294160en_HK
dc.identifier.scopusauthoridWattsgård, C=6602244234en_HK
dc.identifier.scopusauthoridWestgren, U=7004173770en_HK
dc.identifier.scopusauthoridWestphal, O=7005030214en_HK
dc.identifier.scopusauthoridÅman, J=7006018152en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats